Cinqair

Drug Overview

In the advanced field of Pulmonology, treating severe, persistent airway disease requires moving beyond broad-spectrum treatments to highly specific, individualized approaches. For patients living with the daily struggle of severe eosinophilic asthma, Cinqair offers a specialized intervention. Categorized under the Interleukin-5 Antagonist Drug Class, this medication represents a powerful Biologic designed to halt the specific inflammatory cascade that standard treatments cannot control.

This therapy is a Targeted Therapy created to aid patients who suffer from frequent, life-threatening asthma attacks despite using maximum standard controller medications. Addressing the root immune system dysfunction causing lung inflammation, it provides significant relief and respiratory stability.

• Generic Name: reslizumab
• US Brand Names: Cinqair
• Drug Category: Pulmonology
• Drug Class: Interleukin-5 Antagonist
• Route of Administration: Intravenous (IV) infusion
• FDA Approval Status: FDA-approved as an add-on maintenance treatment for patients aged 18 years and older with severe asthma of an eosinophilic phenotype.

What Is It and How Does It Work? (Mechanism of Action)

To understand this medication, one must understand the role of eosinophils in the immune system. Eosinophils are a specific type of white blood cell. In healthy individuals, they fight parasitic infections. However, in patients with severe eosinophilic asthma, the immune system overproduces these cells. They accumulate in the lung tissue, releasing toxic proteins and inflammatory chemicals that cause severe airway swelling, thick mucus production, and airway narrowing.

Cinqair is a monoclonal antibody—a laboratory-produced protein designed to bind to a specific target in the body. In this case, the target is interleukin-5 (IL-5). IL-5 is the primary signaling cytokine (messenger protein) responsible for the growth, maturation, activation, and survival of eosinophils in the bone marrow and their recruitment into the lungs.

At the molecular level, reslizumab specifically binds to circulating IL-5. By binding to IL-5, the drug blocks this cytokine from attaching to the IL-5 receptor complex on the surface of eosinophils. Without the IL-5 signal, eosinophil production in the bone marrow shuts down, and the eosinophils already present in the bloodstream and lung tissue undergo rapid apoptosis (programmed cell death). This direct monoclonal antibody targeting of IL-5 completely interrupts the inflammatory cycle. Unlike a traditional Bronchodilator that simply forces smooth muscles to relax, this Biologic prevents the airway from becoming inflamed and swollen in the first place.

FDA-Approved Clinical Indications

Primary Indication

The primary FDA-approved indication for Cinqair is the add-on maintenance treatment of severe asthma with an eosinophilic phenotype in adults (aged 18 and older). It is prescribed when a patient’s asthma remains poorly controlled despite adherence to a high-dose Inhaled Corticosteroid (ICS) and other controller medications.

Other Approved & Off-Label Uses

While its primary label is highly specific, ongoing clinical practice in Pulmonology occasionally explores its use in related eosinophil-driven diseases:

• Eosinophilic Granulomatosis with Polyangiitis (EGPA): Used off-label for this rare autoimmune condition that causes blood vessel inflammation and severe asthma.
• Hypereosinophilic Syndrome (HES): Investigated for reducing dangerous levels of eosinophils affecting multiple organs.
• Nasal Polyposis: Off-label use for severe chronic rhinosinusitis with nasal polyps driven by high eosinophil levels.
• Primary Pulmonology Indications:
  • Improve Ventilation: By depleting eosinophils, it reduces severe submucosal airway swelling and mucous plugging, keeping the breathing passages open and functional.
  • Reduce Exacerbations: It directly prevents the acute, severe spikes in lung inflammation that cause emergency room visits and hospitalizations.
  • Slow the Decline of Lung Function: By stopping constant inflammatory tissue damage, it preserves the structural integrity of the lungs over the patient’s lifetime.

Dosage and Administration Protocols

Because Cinqair is administered via intravenous infusion, it ensures 100% bioavailability directly into the bloodstream. It must be administered in a clinical setting equipped to handle severe allergic reactions.

Export to Sheets

Dose Adjustments and Specific Instructions:

• Weight-Based Dosing: The dose is strictly calculated based on the patient’s total body weight. The pharmacy must prepare the specific milligram amount in a sterile saline bag prior to the infusion appointment.
• Pediatric Restrictions: This medication is not approved for pediatric use; it is strictly indicated for adults.
• Administration Setting: Patients must be observed by a healthcare professional during the infusion and for an appropriate period afterward due to the risk of anaphylaxis.

Dosage must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

Clinical study data (spanning 2020 to 2026) reinforces Cinqair as a highly effective Targeted Therapy for the right patient population. Efficacy is highly dependent on proper patient selection, specifically identifying those with elevated baseline blood eosinophil counts (typically greater than 400 cells/microliter).

In robust clinical trials, patients receiving reslizumab demonstrated a 50% to 60% reduction in their annual rate of severe clinical asthma exacerbations compared to those receiving a placebo. This translates directly to fewer emergency room visits, fewer days missed from work, and a drastic reduction in the need for damaging systemic oral corticosteroid bursts.

Regarding respiratory metrics, patients experience significant improvements in their Forced Expiratory Volume in one second (FEV1). Data consistently shows an FEV1 improvement ranging from 110 mL to 160 mL over placebo, an increase that patients can feel in their daily ability to breathe deeply. Furthermore, quality of life, measured by the Asthma Control Questionnaire (ACQ), shows sustained, clinically meaningful improvements. Patients report better sleep, less daily coughing, and improved exercise tolerance, which correlates with improved 6-minute walk distance (6MWD) in functionally limited adults.

Safety Profile and Side Effects

Black Box Warning: Cinqair carries a Black Box Warning for Anaphylaxis. Anaphylaxis (a severe, potentially life-threatening allergic reaction) has been reported in approximately 0.3% of patients during or within 20 minutes after completion of the infusion. Because of this, it must be administered by a healthcare professional in a clinical setting prepared to manage anaphylaxis immediately.

Common side effects (>10%):

• Oropharyngeal pain (throat pain).
• Elevated creatine phosphokinase (CPK) levels in the blood, which can indicate mild muscle stress.
• Myalgia (muscle aches and pain).

Serious adverse events:

• Anaphylaxis: Symptoms include breathing difficulties, swelling of the face and throat, sudden drop in blood pressure, and fainting.
• Malignancy Risk: As an immunomodulator, there is a theoretical, albeit extremely low, observed imbalance in malignancies compared to placebo, requiring routine age-appropriate cancer screening.
• Parasitic Infections: Because eosinophils fight helminth (worm) infections, depleting them could theoretically worsen an existing parasitic infection.

Management Strategies:

• Post-Infusion Observation: Mandatory vital sign monitoring and physical observation for at least 30 minutes following every infusion.
• Epinephrine Availability: Immediate access to epinephrine autoinjectors and resuscitation equipment during administration.
• Rescue Inhaler Use: Patients must continue to carry a rapid-acting rescue inhaler for sudden bronchospasms, as this drug is not a rescue medication.

Research Areas

Direct Clinical Connections

Current research suggests Cinqair (reslizumab) may help halt or reverse airway remodeling in severe eosinophilic asthma. By depleting eosinophils, it may reduce chronic inflammation, limit subepithelial fibrosis, decrease mucus gland hypertrophy, and support partial restoration of normal airway epithelial structure and function.

Generalization

Current trials (2020–2026) assess the long-term safety of IL-5 antagonists. Research is also focused on improving delivery methods. Although reslizumab is currently intravenous, developers are investigating biosimilars or structural modifications that could enable subcutaneous auto-injector formulations, improving convenience and adherence.

Severe Disease & Precision Medicine

This drug highlights precision medicine in severe asthma. Biologic phenotyping distinguishes eosinophilic from neutrophilic asthma using blood tests, guiding IL-5 therapy use. This improves treatment accuracy, prevents ineffective therapy, reduces steroid exposure, and lowers the risk of respiratory failure 

Patient Management and Clinical Protocols

Pre-treatment Assessment

Before initiating therapy, rigorous evaluation confirms asthma phenotype and baseline lung function. This includes spirometry (PFTs), imaging (X-ray/CT), and pulse oximetry. Key biomarkers include blood eosinophils (≥400 cells/mcL), FeNO levels, and IgE or allergy testing. Medication adherence, inhaler technique, and smoking history are also assessed for accurate treatment selection 

Monitoring and Precautions

Management of severe asthma is an ongoing, dynamic process.

• Vigilance: Continuous monitoring of symptom control using validated tools like the Asthma Control Test (ACT) at every clinic visit. A primary goal of therapy is a slow, medically supervised “Step-down” protocol to reduce or eliminate the patient’s reliance on daily oral corticosteroids (like prednisone).
• Lifestyle: Absolute smoking cessation is mandatory; smoking actively destroys lung tissue and severely limits drug efficacy. Patients should practice avoidance of known environmental triggers, engage in structured pulmonary rehabilitation exercises, and maintain updated vaccination records (Flu and Pneumonia).

“Do’s and Don’ts” List:

• DO keep all scheduled infusion appointments every 4 weeks to maintain steady drug levels.
• DO continue taking all daily maintenance inhalers, especially your Inhaled Corticosteroid (ICS), unless specifically told to stop by your pulmonologist.
• DO report any signs of an allergic reaction (hives, face swelling, dizziness) immediately.
• DON’T stop taking daily oral steroids abruptly after starting this medication; weaning must be strictly managed by a doctor to prevent adrenal crisis.
• DON’T use this intravenous medication to treat a sudden, acute asthma attack.

Legal Disclaimer

The medical information provided in this document is intended for educational and informational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the direct advice of a qualified healthcare provider or pulmonologist regarding any medical condition, symptom, or treatment plan. Never disregard professional medical advice or delay in seeking it because of information contained herein.